EVENT: New Breakthroughs and The Regulatory Pathway for Personalized Medicine
What are the new therapies? What does this mean for patient care generally and how does it fit into the US reimbursement model for approval and payment?
Please join Arent Fox LLP on Monday, September 18 for an engaging policy discussion on personalized medicine and how it fits into today’s ever changing regulatory landscape. From genetic sequencing of a patient’s tumor to determining how individual patients react to particular medicines, there is much to learn about how the nature of medical practice is changing and will continue to reflect the intersection of genetics, science, and technology.
In this exciting forum, we will learn the following from our speakers:
- What are these new therapies and what do they mean for patient care?
- What are the hurdles for development and commercialization?
- How does personalized medicine fit into the realm of approvals and reimbursement?
We are pleased to announce Dr. Carrie Wolinetz, Associate Director for Science Policy and Chief of Staff for Dr. Francis Collins of the National Institutes of Health, as the keynote speaker.
This program will feature a special presentation by Troy Cox, Chief Executive Officer of Foundation Medicine.
The panel will include several noted policy leaders from Arent Fox, government, and academia:
- Dr. Richard Bankowitz, Executive Vice President for Clinical Affairs, America's Health Insurance Plans (AHIP)
- Dr. Subha Madhavan, Director of Clinical Research Informatics, Georgetown Lombardi Comprehensive Cancer Center
- Dr. Peter Marks, Director, FDA Center for Biologics Evaluation and Research